Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan

Radiotherapy and Oncology

Volumn 91, Issue 3, 2009, Pages 386-392

  Aerts, Hugo J W L ^a   van Baardwijk, Angela A W ^a   Petit, Steven F ^a   Offermann, Claudia ^a   Loon, Judith van ^a   Houben, Ruud ^a   Dingemans, Anne Marie C ^b   Wanders, Rinus ^a   Boersma, Liesbeth ^a   Borger, Jacques ^a   Bootsma, Gerben ^c   Geraedts, Wiel ^c   Pitz, Cordula ^d   Simons, Jean ^e   Wouters, Bradly G ^a   Oellers, Michel ^a   Lambin, Philippe ^a   Bosmans, Geert ^a   Dekker, Andre L A J ^a   Ruysscher, Dirk De ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e Laurentius Hospital ^*  (Netherlands)

Author keywords

Intra tumour heterogeneity; Non small cell lung cancer; PET CT; Radio resistance; Residual metabolic activity

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 65649140133     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.03.006     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Betticher D.C., Hsu Schmitz S.F., Totsch M., et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94 (2006) 1099-1106
3. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
4. Garrido P., Gonzalez-Larriba J.L., Insa A., et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25 (2007) 4736-4742
5. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
6. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung cancer (Amsterdam, Netherlands) 46 (2004) 87-98
7. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
8. Schaake-Koning C., van den Bogaert W., Dalesio W., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl J Med 326 (1992) 524-530
9. Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 32 (2005) S111-113
10. Rojas A.M., Lyn B.E., Wilson E.M., et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 107 (2006) 1321-1330
11. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19 (2001) 127-136
12. Belderbos J.S., Heemsbergen W.D., De Jaeger K., Baas P., and Lebesque J.V. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Rad Oncol Biol Phys 66 (2006) 126-134
13. De Ruysscher D., Wanders R., van Haren E., et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Rad Oncol Biol Phys 71 (2008) 132-138
14. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Rad Oncol Biol Phys 71 (2008) 1394-1401
15. Fowler J.F., Tome W.A., Fenwick J.D., and Mehta M.P. A challenge to traditional radiation oncology. Int J Rad Oncol Biol Phys 60 (2004) 1241-1256
16. Cooper R.A., Carrington B.M., Loncaster J.A., et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57 (2000) 53-59
17. Schutze C., Bergmann R., Yaromina A., et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 83 (2007) 311-315
18. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
19. Vanderstraeten B., Duthoy W., De Gersem W., De Neve W., and Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 79 (2006) 249-258
20. Tanderup K., Olsen D.R., and Grau C. Dose painting: art or science?. Radiother Oncol 79 (2006) 245-248
21. Piert M., Machulla H.J., Picchio M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
22. Foo S.S., Abbott D.F., Lawrentschuk N., and Scott A.M. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 6 (2004) 291-305
23. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97 (2000) 9226-9233
24. Borst G.R., Belderbos J.S., Boellaard R., et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41 (2005) 1533-1541
25. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
26. Eschmann S.M., Friedel G., Paulsen F., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 33 (2006) 263-269
27. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
28. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17 (1999) 3201-3206
29. Mac Manus M.P., Hicks R.J., Matthews J.P., Wirth A., Rischin D., and Ball D.L. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer (Amsterdam, Netherlands) 49 (2005) 95-108
30. Aerts H.J., Bosmans G., van Baardwijk A.A., et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Rad Oncol Biol Phys 71 (2008) 1402-1407
31. Petit S.F., Aerts H.J.W.L., Van Loon J.E.M., et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): An exploratory clinical study. Radiother Oncol 91 (2009) 392-397
32. ICRU Report 50, Prescribing, recording, and reporting photon beam therapy. International Commission on Radiation Units and Measurements. Oxford University Press: Oxford, UK; 1993.
33. Nijsten S.M., Mijnheer B.J., Dekker A.L., Lambin P., and Minken A.W. Routine individualised patient dosimetry using electronic portal imaging devices. Radiother Oncol 83 (2007) 65-75
34. A'Hern R.P. Sample size tables for exact single-stage phase II designs. Stat Med 20 (2001) 859-866
35. Bentzen S.M. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 139 (2008) 41-62
36. Sovik A., Malinen E., Skogmo H.K., Bentzen S.M., Bruland O.S., and Olsen D.R. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Rad Oncol Biol Phys 68 (2007) 1496-1504
37. Thorwarth D., Eschmann S.M., Paulsen F., and Alber M. Hypoxia dose painting by numbers: a planning study. Int J Rad Oncol Biol Phys 68 (2007) 291-300